You searched for "AMN"
Neovascular AMD: fresh recommendations underline standards of best practice
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...A look into the IOL space
Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...UKISCRS to create series of webinars
The first webinar, hosted by Professor David Spalton, will be held today Thursday 9 April, 6-7pm.Optos announces new ultra-widefield colour image modality, providing additional retinal visualisation to eyecare professionals
Optos, Plc, the leading retinal imaging company, announces it is expanding the optomap® ultra-widefield (UWF™) retinal imaging modalities available with the California FA device to further assist eyecare professionals in disease management and treatment planning.
Ophthalmology (third edition)
If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
